Skip to Content

Capozide 50 / 25 Side Effects

Generic Name: captopril / hydrochlorothiazide

Note: This page contains information about the side effects of captopril / hydrochlorothiazide. Some of the dosage forms included on this document may not apply to the brand name Capozide 50 / 25.

For the Consumer

Applies to captopril / hydrochlorothiazide: oral tablet

In addition to its needed effects, some unwanted effects may be caused by captopril / hydrochlorothiazide. In the event that any of these side effects do occur, they may require medical attention.

Severity: Major

You should check with your doctor immediately if any of these side effects occur when taking captopril / hydrochlorothiazide:

More common:
  • Black, tarry stools
  • chest pain
  • chills
  • cough
  • fever
  • painful or difficult urination
  • shortness of breath
  • sore throat
  • sores, ulcers, or white spots on lips or in mouth
  • swollen glands
  • unusual bleeding or bruising
  • unusual tiredness or weakness
Less common:
  • Blurred vision
  • cloudy urine
  • confusion
  • dizziness, faintness, or lightheadedness when getting up from a lying or sitting position suddenly
  • fast, pounding, or irregular heartbeat or pulse
  • sweating
  • Arm, back or jaw pain or discomfort
  • bloody urine
  • chest discomfort
  • chest tightness or heaviness
  • decreased blood pressure
  • decreased frequency or amount of urine
  • dilated neck veins
  • increased need to urinate
  • increased thirst
  • irregular breathing
  • large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • loss of appetite
  • lower back or side pain
  • nausea
  • paleness or cold feeling in fingertips and toes
  • passing urine more often
  • problems in urination or increase in amount of urine
  • swelling of face, fingers, feet or lower legs
  • tingling or pain in fingers or toes when exposed to cold
  • troubled breathing
  • vomiting
  • weight gain
  • wheezing

Severity: Minor

Some of the side effects that can occur with captopril / hydrochlorothiazide may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common:
  • Difficulty in moving
  • itching skin
  • muscle pain or stiffness
  • pain in joints
  • rash
Less common:
  • Change in taste
  • loss of taste

For Healthcare Professionals

Applies to captopril / hydrochlorothiazide: oral tablet


Captopril-hydrochlorothiazide (HCTZ) is generally well tolerated. In some studies, side effects associated with captopril were not seen with the combination because lower doses of captopril were needed to achieve the desired effects. Approximately 3% of patients choose to discontinue therapy due to adverse side effects.[Ref]


Hyperuricemia may be an important consideration in patients with a history of gout. Hypophosphatemia and low serum magnesium concentrations may occur, but are usually clinically insignificant except in malnourished patients.[Ref]

Metabolic side effects including hypokalemia and hypercholesterolemia that are sometimes associated with HCTZ are uncommon with the addition of captopril. In fact, total cholesterol may decrease in some patients with pretreatment hypercholesterolemia. HCTZ monotherapy is associated with hypomagnesemia, hypercalcemia, and elevated serum uric acid levels.[Ref]


Gastrointestinal side effects include dysgeusia in approximately 0.3% to 4.0% of patients. This is probably related to the captopril component, and is usually self-limited and reversible. Nausea is reported in 1% to 4% of patients.[Ref]

Thiazide diuretics may increase serum cholesterol and triglycerides, resulting in increased risk of cholesterol gallstone formation. Reports of bowel strictures associated with thiazide ingestion have been reported in the 1960's, although these patients were on a combination HCTZ-potassium product.[Ref]

Nervous system

Nervous system side effects include minor dizziness in 5% to 10% of patients.[Ref]


Cardiovascular side effects have included hypotension or angina pectoris in 1% to 5% of patients. Less common cardiovascular complaints include tachycardia or palpitations in less than 2% of patients.[Ref]

Hypotension and presyncopal symptoms are more common in patients with congestive heart failure or hyponatremia. "First dose" hypotension may be minimized by starting with lower doses with the patient supine.[Ref]


A retrospective study has revealed a significantly higher incidence of discontinuation of angiotensin converting enzyme inhibitor therapy due to cough among black patients compared with non-black patients (9.6% vs. 2.4%).[Ref]

Respiratory side effects including a dry, persistent cough has been associated with captopril therapy in approximately 4% of patients. Rare reports of asthma associated with captopril suggest that angiotensin-converting enzyme plays a role in the genesis and metabolism of bronchodilatory mediators.[Ref]


Although HCTZ has been used to treat nephrogenic diabetes insipidus, a case in which the drug was believed to have caused this condition has been reported.[Ref]

Renal side effects have included new renal insufficiency (in less than 3% of patients) and proteinuria (1%). When used judiciously in many circumstances, captopril and other ACE inhibitors may contribute to improved renal function. Risk factors for the development of renal insufficiency are hypovolemia, hypotension, hyponatremia, concomitant use of other potentially nephrotoxic medications, and renal artery stenosis. Rare cases of allergic nephritis, membranous glomerulonephritis, and nephrotic syndrome are reported during captopril monotherapy.[Ref]


A 68-year-old man with a history of myocardial infarction (MI) developed dyspnea, chest tightness, a low grade fever, dizziness, sweating, and vomiting associated with cyanosis, a mild leukocytosis, radiographic evidence of pulmonary edema, clinical evidence of hypovolemia, and respiratory acidosis. MI and infection were ruled out; the patient recovered after restoration of his intravascular volume with saline and albumin. The only known precipitating factor was the ingestion of HCTZ, which the patient had taken without incident for two years. Rechallenge resulted in recurrent acute pulmonary edema. Other signs of hypersensitivity, such as rash and eosinophilia, were absent.

Patients with intestinal angioedema generally present with abdominal pain (with or without nausea or vomiting) and in some cases there was no prior history of facial angioedema, and C-1 esterase levels were normal. These symptoms resolve after stopping the ACE inhibitor.[Ref]

Hypersensitivity reactions to captopril, as with some other angiotensin converting enzyme (ACE) inhibitors, may be life-threatening. Angioedema of the face, extremities, lips, tongue, glottis and/or pharynx have been reported rarely in patients receiving ACE inhibitors. Obstructive laryngeal and glossal angioedema due to captopril is a rare, but potentially fatal reaction. In addition, intestinal angioedema has been reported in patients treated with ACE inhibitors. It is recommended that any patient with dyspnea, dysphagia, or significant facial angioedema stop therapy immediately and avoid ACE inhibitor therapy in general. Other hypersensitivity reactions including hepatitis, allergic vasculitis, pruritus, and mild to severe skin rashes have been reported.

Rare cases of acute pulmonary edema, interstitial cystitis, interstitial nephritis and anaphylaxis are associated with HCTZ.[Ref]


The neutropenia and agranulocytosis associated with captopril typically occur within 3 to 12 weeks after starting therapy, and are usually reversible within 3 weeks after stopping the drug. While most cases are described in patients who are receiving high doses of captopril (600 mg per day), agranulocytosis has been described in patients on 12.5 to 100 mg per day.[Ref]

Hematologic side effects have rarely been associated with captopril monotherapy. These include neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia, or thrombocytopenia in approximately 0.02% of patients. Extremely rare cases of immune-complex hemolytic anemia, aplastic anemia, and thrombocytopenia are associated with HCTZ monotherapy.[Ref]


Musculoskeletal complaints are limited to muscular cramping, described almost exclusively with dosage greater than captopril 100 mg-HCTZ 50 mg per day.[Ref]


Endocrinologic problems associated with thiazide diuretics include glucose intolerance and a potentially deleterious effect on the lipid profile. This may be important in some patients with or who are at risk for diabetes or coronary artery disease. A single case of recurrent parathyroid adenoma is reported, although the association is probably coincidental.[Ref]

A prospective study of 34 patients who received oral thiazide diuretics for 14 years without interruption revealed a significantly increased average fasting blood glucose level after treatment. Withdrawal of thiazide therapy for seven months in 10 of the patients resulted in mean reductions of 10% in fasting blood glucose and 25% in the 2-hour glucose tolerance test value. A control group was not reported.[Ref]


A review of 19 cases of captopril-associated hepatic injury revealed the most common dosage of captopril was 450 mg per day, the mean age was 61 years, and the most common interval between starting the drug and the onset of symptoms was 14 weeks. Jaundice was the most common presenting symptom, and approximately one third of the patients had concomitant fever, rash, or eosinophilia. Because of these associated findings, the suspected mechanism of injury was hypersensitivity.[Ref]

Hepatic side effects associated with the use of ACE inhibitors have included a rare syndrome that begins with cholestatic jaundice and progresses to fulminant hepatic necrosis and (sometimes) death. Experts recommend discontinuation of therapy with this drug if jaundice or markedly elevated hepatic serum enzymes develop.[Ref]


Immunologic reactions rarely associated with captopril monotherapy have included lymphadenopathy, systemic lupus erythematosus, and Henoch-Schonlein Purpura. Serum sickness-like illness has also been reported.[Ref]

A 53-year-old man with diabetes mellitus, hypertension, and heart failure developed arthralgias, fever, and malaise associated with bilateral pleural effusion, elevated liver function tests, a pericardial rub, and elevated C-reactive protein. After other causes of systemic lupus erythematosus were ruled out, captopril was stopped, and these signs and symptoms resolved.

In a study of 78 patients who were treated with captopril for 11 months, 13 developed a positive antinuclear antibody titer. Only one of the 13, however, developed a serum sickness-like illness.

There are rare case reports of HCTZ-induced immune hemolytic anemia. The following illustrates a fatal case:

A 53-year-old man with hypertension developed nausea, vomiting, diarrhea, and progressive anorexia and weakness associated with scleral icterus, anemia with spherocytosis, dark red urine with proteinuria, bilirubinuria, hemoglobinuria, and elevated lactic dehydrogenase levels 18 months after beginning HCTZ and methyldopa. Haptoglobin was less than 50 mg per dl. Direct and indirect Coombs' tests were positive. The patient died suddenly; autopsy revealed no obvious cause of death, left ventricular hypertrophy, and mild coronary atherosclerosis.[Ref]


1. Schnaper HW "Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension." Angiology 40 (1989): 389-95

2. Hoss DM, Nierenberg DW "Severe shaking chills and fever following hydrochlorothiazide administration." Am J Med 85 (1988): 747

3. Palmer AJ, Beevers DG, Bulpitt CJ, et al "Mortality associated with captopril and enalapril: a report from the DHSS Hypertension Care Computing Project." J Hypertens 8 (1990): 521-4

4. Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992): 215-23

5. Schoenberger JA, Testa M, Ross AD, et al "Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice." Arch Intern Med 150 (1990): 301-6

6. Ferriere M, Lachkar H, Richard JL, Bringer J, Orsetti A, Mirouze J "Captopril and insulin sensitivity." Ann Intern Med 102 (1985): 134-5

7. Klimiuk PS, Davies M, Adams PH "Primary hyperparathyroidism and thiazide diuretics." Postgrad Med J 57 (1981): 80-3

8. Bain PG, Egner W, Walker PR "Thiazide-induced dilutional hyponatraemia masquerading as subarachnoid haemorrhage ." Lancet 2 (1986): 634

9. Fager G, Berglund G, Bondjers G, Elmfeldt D, Lager I, Olofsson SO, Smith U, Wiklund O "Effects of anti-hypertensive therapy on serum lipoproteins. Treatment with metoprolol, propranolol and hydrochlorothiazide." Artery 11 (1983): 283-96

10. Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5

11. Nicholls MG, Espiner EA, Ikram H, Maslowski AH "Hyponatraemia in congestive heart failure during treatment with captopril." Br Med J 281 (1980): 909

12. Giuntoli F, Gabbani S, Natali A, et al "Captopril treatment in elderly hypertensive patients: efficacy and tolerability." J Hypertens Suppl 7 (1989): s57-8

13. Balizet L "Recurrent parathyroid adenoma. Association with prolonged thiazide administration." JAMA 225 (1973): 1238-9

14. Warren SE, O'Connor DT "Hyperkalemia resulting from captopril administration." JAMA 244 (1980): 2551-2

15. "Product Information. Capozide (hydrochlorothiazide-captopril)." Bristol-Myers Squibb, Princeton, NJ.

16. Ambrosioni E, Borghi C, Costa FV "Captopril and hydrochlorothiazide: rationale for their combination." Br J Clin Pharmacol 23 (1987): 43S-50S

17. Al-Mufti HI, Arieff AI "Captopril-induced hyponatremia with irreversible neurologic damage." Am J Med 79 (1985): 769-71

18. Hollifield JW, Slaton PE "Thiazide diuretics, hypokalemia and cardiac arrhythmias." Acta Med Scand Suppl 647 (1981): 67-73

19. Houston MC "Adverse effects of antihypertensive drug therapy on glucose intolerance." Cardiol Clin 4 (1986): 117-35

20. Atkinson AB, Brown JJ, Leckie B, Fraser R, Lever AF, Robertson JI "Captopril in a hyponatraemic hypertensive: need for caution in initiating therapy." Lancet 1 (1979): 557-8

21. Luccioni R, Sever PS, Diperri T, Redon J, Laurandin I, Brault Y, Chastang C, Guez D, Andrejak M, Araud JM, Aupy JM, Baclet J "An equivalence study of the safety and efficacy of a fixed-dose combination of perindopril with indapamide versus fixed-dose combinations of captopril with hydrochlorothiazide and enalapril with hydrochlorothiazide in the treatment of hypertension." J Hypertens 13 (1995): 1847-51

22. McGrath BP, Matthews PG, Louis W, Howes L, Whitworth JA, Kincaid-Smith PS, Fraser I, Scheinkestel C, MacDonald G, Rallings M "Double-blind study of dilevalol and captopril, both in combination with hydrochlorothiazide, in patients with moderate to severe hypertension." J Cardiovasc Pharmacol 16 (1990): 831-8

23. Bagdade JD, Buchanan WF, Pollare T, Lithell H "Effects of hydrochlorothiazide and captopril on lipoprotein lipid composition in patients with essential hypertension." Eur J Clin Pharmacol 49 (1996): 355-9

24. Pinnock CA "Hyponatraemia associated with hydrochlorothiazide treatment ." Br Med J 1 (1978): 48

25. Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,

26. Byatt CM, Millard PH, Levin GE "Diuretics and electrolyte disturbances in 1000 consecutive geriatric admissions." J R Soc Med 83 (1990): 704-8

27. Holland OB, Kuhnert L, Pollard J, Padia M, Anderson RJ, Blomqvist G "Ventricular ectopic activity with diuretic therapy." Am J Hypertens 1 (1988): 380-5

28. Huang HS, Reynertson RH, Boshell BR "Severe hyponatremia associated with captopril therapy." Ala J Med Sci 21 (1984): 142-4

29. Mouallem M, Friedman E, Shemesh Y, Mayan H, Pauzner R, Farfel Z "Cardiac conduction defects associated with hyponatremia." Clin Cardiol 14 (1991): 165-8

30. Ragnarsson J, Hardarson T, Snorrason SP "Ventricular dysrhythmias in middle-aged hypertensive men treated either with a diuretic agent or a beta-blocker." Acta Med Scand 221 (1987): 143-8

31. Polanska AI, Baron DN "Hyponatraemia associated with hydrochlorothiazide treatment ." Br Med J 1 (1978): 175-6

32. Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860

33. Papademetriou V, Fletcher R, Khatri IM, Freis ED "Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias." Am J Cardiol 52 (1983): 1017-22

34. Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P "Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy." Am J Med 89 (1990): 811-3

35. Seelig CB "Magnesium deficiency in two hypertensive patient groups." South Med J 83 (1990): 739-42

36. Costa FV, Borghi C, Boschi S, Ambrosioni E "Differing dosages of captopril and hydrochlorothiazide in the treatment of hypertension: long-term effects metabolic values and intracellular electrolytes." J Cardiovasc Pharmacol 7 (1985): S70-6

37. Benfield GF, Haffner C, Harris P, Stableforth DE "Dilutional hyponatraemia masquerading as subarachnoid haemorrhage in patient on hydrochlorothiazide/amiloride/timolol combined drug ." Lancet 2 (1986): 341

38. Nicholls MG, Maslowski AH, Ikram H, Espiner EA "Ulceration of the tongue: a complication of captopril therapy." Ann Intern Med 94 (1981): 659

39. Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967): 7-11

40. Walley T, Winstanley P, Roberts D, et al "Adverse effects of captopril in hospital outpatients with hypertension." Postgrad Med J 66 (1990): 106-9

41. Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966): 97-101

42. Bellary SV, Isaacs PE, Scott AW "Captopril and the liver." Lancet 2 (1989): 514

43. Lederle RM "Captopril and hydrochlorothiazide in the fixed combination multicenter trial." J Cardiovasc Pharmacol 7 (1985): S63-9

44. Shionoiri H, Nomura S, Oda H, et al "Hepatitis associated with captopril and enalapril but not with delapril in a patient with congestive heart failure receiving chronic hemodialysis." Curr Ther Res Clin Exp 42 (1987): 1171-6

45. Critchley JAJH, Gilchrist N, Ikeda L, Dubois C, Bradstreet DC, Shaw WC, Goldberg AI, Sweet CS "A randomized, double-masked comparison of the antihypertensive efficacy and safety of combination therapy with losartan and hydrochlorothiazide versus captopril and hydrochlorothiazide in elderly and younger patients." Curr Ther Res Clin Exp 57 (1996): 392-407

46. Ohman P, Aurell M, Asplund J, et al "A long-term follow-up of patients with essential hypertension treated with captopril." Acta Med Scand 216 (1984): 53-6

47. Al Mahdy H, Boswell GV "Captopril-induced oesophagitis." Eur J Clin Pharmacol 34 (1988): 95

48. Viraben R, Adoue D, Dupre A, Touron P "Erosions and ulcers of the mouth ." Arch Dermatol 118 (1982): 959

49. Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967): 136-8

50. Boyd I "Captopril-induced taste disturbance." Lancet 342 (1993): 304

51. Zazgornik J, Kaiser W, Biesenbach G "Captopril-induced dysgeusia." Lancet 341 (1993): 1542

52. Chakraborty TK, Ruddell WS "Guillain-Barre neuropathy during treatment with captopril." Postgrad Med J 63 (1987): 221-2

53. Sandyk R "Parkinsonism induced by captopril ." Clin Neuropharmacol 8 (1985): 197-8

54. Fogari R, Zoppi A, Tettamanti F, Tettamanzi D, Lusardi P, Motolese M "Evaluation by 24-hour ambulatory blood pressure monitoring of efficacy of benazepril 20 mg plus hydrochlorothiazide 25 mg fixed combination as compared to captopril 25mg plus hydrochlorothiazide 25 mg fixed combination in treating mild to moderate..." J Cardiovasc Pharmacol 24 (1994): 687-93

55. Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981): 508-16

56. Rapoport S, Zyman P "Captopril and central nervous system effects ." Ann Intern Med 98 (1983): 1023

57. Brogden RN, Todd PA, Sorkin EM "Captopril: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure." Drugs 36 (1988): 540-600

58. Zatuchni J "Captopril pericarditis ." JAMA 251 (1984): 343-4

59. Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987): 529-36

60. Young BA "ACE inhibitor first dose effect." Med J Aust 158 (1993): 577

61. Chu TJ, Chow N "Adverse effects of ACE inhibitors." Ann Intern Med 118 (1993): 314;

62. Davis JB "Chest pain after captopril ." Br Med J 296 (1988): 214

63. Black J, Hunt TL, Godley PJ "Initiation of captopril therapy: the first-dose effect." J Clin Pharmacol 26 (1986): 539-40

64. Baker KM, Johns DW, Ayers CR, Carey RM "Ischemic cardiovascular complications concurrent with administration of captopril: a clinical note." Hypertension 2 (1980): 73-4

65. Hoegholm A, Rasmussen SW, Kristensen KS "Pulmonary oedema with shock induced by hydrochlorothiazide: a rare side effect mimicking myocardial infarction." Br Heart J 63 (1990): 186

66. Levay ID "Hydrochlorothiazide-induced pulmonary edema." Drug Intell Clin Pharm 18 (1984): 238-9

67. Dorn MR, Walker BK "Noncardiogenic pulmonary edema associated with hydrochlorothiazide therapy." Chest 79 (1981): 482-3

68. Klein MD "Noncardiogenic pulmonary edema following hydrochlorothiazide ingestion." Ann Emerg Med 16 (1987): 901-3

69. Alted E, Navarro M, Cantalapiedra JA, Alvarez JA, Blasco MA, Nunez A "Non-cardiogenic pulmonary edema after oral ingestion of hydrochlorothiazide ." Intensive Care Med 13 (1987): 364-5

70. Cazzola M, Matera MG, Liccardi G, Deprisco F, Damato G, Rossi F "Theophylline in the inhibition of angiotensin-converting enzyme inhibitor-induced cough." Respiration 60 (1993): 212-5

71. Elliott WJ "Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects." Clin Pharmacol Ther 60 (1996): 582-8

72. Lipworth BJ, McMurray JJ, Clark RA, Struthers AD "Development of persistent late onset asthma following treatment with captopril." Eur Respir J 2 (1989): 586-8

73. Andrejak M, Andrejak MT, Osterman G "Enalapril, captopril, and cough ." Arch Intern Med 148 (1988): 249

74. Mitchell A, Gillies A, Carney S, Smith AJ "Cough and captopril ." Arch Intern Med 146 (1986): 1017

75. Grace AA, Morgan AD, Strickland NH "Hydrochlorothiazide causing unexplained pulmonary oedema." Br J Clin Pract 43 (1989): 79-81

76. Popa V "Captopril-related (and -induced?) asthma." Am Rev Respir Dis 136 (1987): 999-1000

77. Biron P, Dessureault J, Napke E "Acute allergic interstitial pneumonitis induced by hydrochlorothiazide [published erratum appears in Can Med Assoc J 1991 Sep 1;145(5):391]." Can Med Assoc J 145 (1991): 28-34

78. Silas JH, Klenka Z, Solomon SA, Bone JM "Captopril induced reversible renal failure: a marker of renal artery stenosis affecting a solitary kidney." Br Med J 286 (1983): 1702-3

79. Packer M, Lee WH, Medina N, et al "Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure." Ann Intern Med 106 (1987): 346-54

80. Hoorntje SJ, Donker AJ, Prins EJ, Weening JJ "Membranous glomerulopathy in a patient on captopril." Acta Med Scand 208 (1980): 325-9

81. Cooke HM, Debesse A "Angiotensin converting enzyme inhibitor-induced renal dysfunction - recommendations for prevention." Int J Clin Pharmacol Ther 32 (1994): 65-70

82. Fotino S, Sporn P "Nonoliguric acute renal failure after captopril therapy." Arch Intern Med 143 (1983): 1252-3

83. Case DB, Atlas SA, Mouradian JA, et al "Proteinuria during long-term captopril therapy." JAMA 244 (1980): 346-9

84. Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982): 214-9

85. Hays R, Aquino A, Lee BB, et al "Captopril-induced acute renal failure in a kidney transplant recipient." Clin Nephrol 19 (1983): 320-1

86. Atkinson AB, Brown JJ, Lever AF, et al "Neurological dysfunction in two patients receiving captopril and cimetidine ." Lancet 2 (1980): 36-7

87. Textor SC, Gephardt GN, Bravo EL, et al "Membranous glomerulopathy associated with captopril therapy." Am J Med 74 (1983): 705-12

88. Pierpont GL, Levine TB, Cohn JN "Azotemia in patients with congestive heart failure treated with captopril." Minn Med 66 (1983): 223-5

89. Chrysant SG, Dunn M, Marples D, DeMasters K "Severe reversible azotemia from captopril therapy: report of three cases and review of the literature." Arch Intern Med 143 (1983): 437-41

90. Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983): 530-7

91. Rosendorff C, Milne FJ, Levy H, et al "Nephrotic syndrome during captopril therapy." S Afr Med J 58 (1980): 172-3

92. Steinman TI, Silva P "Acute renal failure, skin rash, and eosinophilia associated with captopril therapy." Am J Med 75 (1983): 154-6

93. Seedat YK "Nephrotic syndrome from captopril ." S Afr Med J 57 (1980): 390

94. Hoorntje SJ, Kallenberg CG, Weening JJ, et al "Immune-complex glomerulopathy in patients treated with captopril." Lancet 1 (1980): 1212-5

95. Mujais SK, Fouad FM, Textor SC, et al "Transient renal dysfunction during initial inhibition of converting enzyme in congestive heart failure." Br Heart J 52 (1984): 63-71

96. Luderer JR, Schoolwerth AC, Sinicrope R, et al "Acute renal failure, hemolytic anemia and skin rash associated with captopril therapy." Am J Med 71 (1981): 493-6

97. van Son WJ, van der Woude FJ, Tegzess AM, et al "Captopril-induced deterioration of graft function in patients with a transplant renal artery stenosis." Proc Eur Dial Transplant Assoc 20 (1983): 325-30

98. Engelman K "Is there proof that captopril causes proteinuria?" Arch Intern Med 162 (2002): 842-3

99. Laaban J, Marie JP, Wallach D, et al "Necrotising vasculitis associated with captopril therapy." Eur Heart J 8 (1987): 319

100. Borders JV "Captopril and onycholysis ." Ann Intern Med 105 (1986): 305-6

101. Jett GK "Captopril-induced angioedema ." Ann Emerg Med 13 (1984): 489-90

102. Puppin D Jr, Rybojad M, de la Chapelle C, Morel P "Kaposi's sarcoma associated with captopril ." Lancet 336 (1990): 1251-2

103. Solinger AM "Exfoliative dermatitis from captopril." Cutis 29 (1982): 473-4

104. Pascual J, Medina S, Teruel JL, et al "Captopril-induced lichenoid eruption in an uremic patient." Nephron 56 (1990): 110-2

105. Larbre JP, Nicolas JF, Collet P, et al "Kaposi's sarcoma in a patient with rheumatoid arthritis possible responsibility of captopril in the development of lesions." J Rheumatol 18 (1991): 476-7

106. Kubo SH, Cody RJ "Enalapril, a rash, and captopril ." Ann Intern Med 100 (1984): 616

107. Kidney JC, O'Halloran DJ, FitzGerald MX "Captopril and lymphocytic alveolitis." Br Med J 299 (1989): 981

108. Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986): 336-8

109. Clement MI "Captopril-induced eruptions ." Arch Dermatol 117 (1981): 525-6

110. Parfrey PS, Clement M, Vandenburg MJ, Wright P "Captopril-induced pemphigus." Br Med J 281 (1980): 194

111. Wood SM, Mann RD, Rawlins MD "Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors." Br Med J 294 (1987): 91-2

112. Wilkin JK, Hammond JJ, Kirkendall WM "The captopril-induced eruption: a possible mechanism, cutaneous kinin potentiation." Arch Dermatol 116 (1980): 902-5

113. Jason DR "Fatal angioedema associated with captopril." J Forensic Sci 37 (1992): 1418-21

114. Seidman MD, Lewandowski CA, Sarpa JR, et al "Angioedema related to angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 102 (1990): 727-31

115. Goodfield MJ, Millard LG "Severe cutaneous reactions to captopril." Br Med J 290 (1985): 1111

116. Hedner T, Samuelsson O, Lunde H, et al "Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors." Br Med J 304 (1992): 941-6

117. Luderer JR, Lookingbill DP, Schneck DW, et al "Captopril-induced skin eruptions." J Clin Pharmacol 22 (1982): 151-9

118. Wolf R, Tamir A, Brenner S "Psoriasis related to angiotensin-converting enzyme inhibitors." Dermatologica 181 (1990): 51-3

119. Leaker B, Whitworth JA "Alopecia associated with captopril treatment ." Aust N Z J Med 14 (1984): 866

120. Werber JL, Pincus RL "Oropharyngeal angioedema associated with the use of angiotensin-converting enzyme inhibitors." Otolaryngol Head Neck Surg 101 (1989): 96-8

121. Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989): 187-8

122. Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991): 399-400

123. Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985): 106-7

124. el-Makri A, Larabi MS, Kechrid C, et al "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981): 277-8

125. Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989): s27-30

126. Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980): 927-8

127. Shindo K, Matsuya F, Ura T, et al "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984): 314-6

128. Gavras I, Graff LG, Rose BD, et al "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981): 58-9

129. Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990): 543-4

130. Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981): 166

131. Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989): 189-90

132. Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980): 927-8

133. Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985): 320-2

134. Devlin RG, Fleiss PM "Captopril in human blood and breast milk." J Clin Pharmacol 21 (1981): 110-3

135. Hirakata H, Onoyama K, Iseki K, et al "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984): 355-60

136. Parker WA "Captopril-induced cholestatic jaundice." Drug Intell Clin Pharm 18 (1984): 234-5

137. Rahmat J, Gelfand RL, Gelfand MC, et al "Captopril-associated cholestatic jaundice." Ann Intern Med 102 (1985): 56-8

138. Zimran A, Abraham AS, Hershko C "Reversible cholestatic jaundice and hyperamylasaemia associated with captopril treatment." Br Med J 287 (1983): 1676

139. Hagley MT, Hulisz DT, Burns CM "Hepatotoxicity associated with angiotensin-converting enzyme inhibitors." Ann Pharmacother 27 (1993): 228-31

140. Tabibian N, Alpert L, Alpert E "Captopril-induced liver dysfunction." South Med J 80 (1987): 1173-5

141. Shirey RS, Bartholomew J, Bell W, Pollack B, Kickler TS, Ness PM "Characterization of antibody and selection of alternative drug therapy in hydrochlorothiazide-induced immune hemolytic anemia." Transfusion 28 (1988): 70-2

142. Bertin P, Kamdem J, Bonnet C, Arnaud M, Treves R "Captopril-induced lupus." Clin Exp Rheumatol 11 (1993): 695

143. Sarui H, Sano A, Maruyama T, Nakashima K, Takeda N, Yasuda K "Severe graves ophthalmopathy accompanied by HTLV-1-associated uveitis (HAU) and anti-neutrophil cytoplasmic antibody-related vasculitis: a case report and a review of the literature of HAU with Graves disease." Am J Med Sci 324 (2002): 109-14

144. Sieber C, Grimm E, Follath F "Captopril and systemic lupus erythematosus syndrome." Br Med J 301 (1990): 669

145. Aberg H, Morlin C, Frithz G "Captopril-associated lymphadenopathy." Br Med J 283 (1981): 1297-8

146. Kallenberg CG, Hoorntje SJ, Smit AJ, et al "Antinuclear and antinative DNA antibodies during captopril treatment." Acta Med Scand 211 (1982): 297-300

147. Beck ML, Cline JF, Hardman JT, Racela LS, Davis JW "Fatal intravascular immune hemolysis induced by hydrochlorothiazide." Am J Clin Pathol 81 (1984): 791-4

Not all side effects for Capozide 50 / 25 may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.